LevitasBio Launches LeviSelect Suite of Cell Depletion & Enrichment Kits

LevitasBio, Inc. (www.levitasbio.com), a premier end-to-end sample processing and cellular analysis provider to the life sciences market, unveils a suite of LeviSelect™ cell depletion and enrichment kits for immunology research.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230207005645/en/

LeviSelect Kits are a targeted expansion of the revolutionary LeviCell™ Advanced Workflow fully integrated protocol that delivers an important new approach to cellular isolation and analysis, offering:

• Cells of interest are entirely label-free, unmodified or unperturbed with no gene expression or activation changes
• Live-cell enrichment, debris removal, and targeted selection all occur in a single simple step with no additional purifications, filtrations or consumables required
• Multiple LeviSelect kits can be multiplexed for a powerful and extremely targeted approach

For oncology or immuno-oncology research, LeviSelect CD45 Depletion Kits provide a highly effective method for the enrichment of pure tumor cells enabling characterization for drug discovery and biomarker identification.

LeviSelect Immune Kits support target selection of the immune subpopulations required for downstream cell analysis or further subsetting. Researchers can enrich hematopoietic populations quickly without lengthy workflows or potential cell activation.

• CD3 Enrichment
• CD4 Enrichment
• CD8 Enrichment
• Pan B Enrichment
• Pan Monocyte Enrichment
• NK Cell Enrichment
• Neutrophil Enrichment

Now T Cells, B Cells, NK Cell and Monocytes can be enriched simultaneously with viable cell enrichment in an untouched and unbiased manner. Future LeviSelect kits will include subtypes from these major populations.

“With the immediate launch of seven LeviSelect Kits—and six more available via our Early Access program—LevitasBio is enabling the streamline enrichment of these cells for downstream cell-based assays or immune profiling studies,” stated Martin Pieprzyk, CEO of LevitasBio. “This is highly impactful to catalyze novel discoveries in both academic and biopharma discovery research.”

Researchers, scientists, and labs who would like exclusive, priority access to future LeviSelect Kits can join the LevitasBio Early Access Program at https://levitasbio.com/early-access-program.

LevitasBio —True Biology Begins Here

Our mission is to advance science and human health by providing researchers with new and powerful methods of cellular analysis. LevitasBio delivers the first truly novel approach to cellular analysis in 30 years. Our proprietary label-free levitation technology enables researchers to rescue and achieve higher quality and quantity of cells without introducing bias, high pressure, or modifications to gene expression profiles, ensuring the integrity of downstream data and analysis is maintained.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230207005645/en/

Contact information

Steven Collier
Communication Liaison
steve@levitasbio.com
650-229-8596